Update Breast Cancer 2023 Part 2 – Advanced-Stage Breast Cancer
نویسندگان
چکیده
Abstract In recent years, a number of new therapies have led to advances in the treatment patients with advanced breast carcinoma. These substances are mainly CDK4/6 inhibitors and other that can overcome endocrine resistance, oral selective estrogen receptor degraders, antibody drug conjugates (ADCs), PARP inhibitors. This review summarizes evaluates latest study results been published months. includes overall survival data Destiny-Breast03 study, first analysis CAPItello-291 comparison inhibitor chemotherapy line therapy (RIGHT Choice study), Destiny-Breast02 setting after T-DM1 treatment, Serena-2 study. Most these studies potential significantly change therapeutic landscape for carcinoma show continued rapid development is always producing results.
منابع مشابه
SHIRAZ BREAST CANCER STUDY PART II: SCREENING MAMMOGRAPHY IN A OPULATIONBASED BREAST CANCER SURVEY
The purpose of this study was to assess the detection rate of mammography in breast cancer and the attendance rate in response to the call for screening mammography in females before the development of symptoms. One-thousand four-hundred and thirty-eight women over 35 years of age who had no complaint and had normal breast examinations were called for mammography. Out of the 10,000 women u...
متن کاملEarly stage breast cancer and radiotherapy: update.
Breast cancer (BC) is the most common malignancy among women. Therapeutic options are based on disease staging, histopathological characteristics, age, and others. The objective of the present study is to carry out an update of the concepts and definitions of radiotherapy (RT) in conservative treatment of early-stage breast cancer, with emphasis on indications, contraindications, RT dose fracti...
متن کاملBreast cancer screening update.
Breast cancer is the most common non-skin cancer and the second leading cause of cancer death in North American women. Mammography is the only screening test shown to reduce breast cancer-related mortality. There is general agreement that screening should be offered at least biennially to women 50 to 74 years of age. For women 40 to 49 years of age, the risks and benefits of screening should be...
متن کاملBreast cancer update.
The large number of excellent presentations on breast cancer at this year's ASCO meeting reflects the enormous interest in clinical trials of this common disease. In the reports of adjuvant hormonal therapy, the most interesting included Abstract 273 by Boccardo et al., who reported that postmenopausal women with estrogen receptor positive (ER(+)) cancers who had already completed three years o...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Geburtshilfe Und Frauenheilkunde
سال: 2023
ISSN: ['1438-8804', '2199-6989', '0016-5751']
DOI: https://doi.org/10.1055/a-2074-0125